trending Market Intelligence /marketintelligence/en/news-insights/trending/_cnruwe65dyotiupc4gqxq2 content esgSubNav
In This List

Breathtec Biomedical appoints CEO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Breathtec Biomedical appoints CEO

Breathtec Biomedical Inc. appointed Christopher Moreau as its CEO.

Moreau is the CEO of NASH Pharmaceuticals Inc., a privately held drug development company. He is also the former president and CEO of Miraculins Inc., where he helped raise over C$13 million to fund research and development for prostate cancer, skin cholesterol and type 2 diabetes.

Breathtec Biomedical is a Canadian company developing breath-analysis technology for the early screening of life-threatening diseases.